These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 29350391)

  • 1. Polish single-centre follow-up of subcutaneous implantable cardioverter-defibrillator (S-ICD) systems implanted for the prevention of sudden cardiac death.
    Kempa M; Budrejko S; Sławiński G; Królak T; Lewicka E; Raczak G
    Kardiol Pol; 2018; 76(2):452-458. PubMed ID: 29350391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
    Rudic B; Tülümen E; Berlin V; Röger S; Stach K; Liebe V; El-Battrawy I; Dösch C; Papavassiliu T; Akin I; Borggrefe M; Kuschyk J
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center.
    Grabowski M; Gawałko M; Michalak M; Cacko A; Kowara M; Kołodzińska A; Januszkiewicz Ł; Balsam P; Vitali Serdoz L; Winter J; Opolski G
    Cardiol J; 2019; 26(4):360-367. PubMed ID: 29611175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.
    Olde Nordkamp LR; Dabiri Abkenari L; Boersma LV; Maass AH; de Groot JR; van Oostrom AJ; Theuns DA; Jordaens LJ; Wilde AA; Knops RE
    J Am Coll Cardiol; 2012 Nov; 60(19):1933-9. PubMed ID: 23062537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subcutaneous implantable cardioverter-defibrillator in prevention of sudden cardiac death in Poland - opinion paper endorsed by the Polish Cardiac Society Working Group on Heart Rhythm].
    Ptaszyński P; Grabowski M; Kowalski O; Kempa M; Mitkowski P; Przybylski A; Sterliński M
    Kardiol Pol; 2017; 75(10):1057-1060. PubMed ID: 29057442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Subcutaneous Cardioverter Defibrillator in Patients at High Risk of Sudden Cardiac Death　- Primary Japanese Experience.
    Sasaki S; Tomita H; Tsurugi T; Ishida Y; Shoji Y; Nishizaki K; Kinjo T; Endo T; Nishizaki F; Hanada K; Sasaki K; Horiuchi D; Kimura M; Higuma T; Okamatsu H; Tanaka Y; Koyama J; Okumura K
    Circ J; 2018 May; 82(6):1546-1551. PubMed ID: 29643282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific indications and clinical outcome in patients with subcutaneous implantable cardioverter-defibrillator (ICD) - A nationwide multicentre registry.
    Sponder M; Khazen C; Dichtl W; Fiedler L; Mörtl D; Teubl A; Steinwender C; Martinek M; Nürnberg M; Dalos D; Kastner J; Schukro C
    Eur J Intern Med; 2018 Feb; 48():64-68. PubMed ID: 28978409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The subcutaneous ICD as an alternative to the conventional ICD system: Initial experience in Greece and a review of the literature.
    Sideris S; Archontakis S; Gatzoulis KA; Anastasakis A; Sotiropoulos I; Arsenos P; Kasiakogias A; Terentes D; Trachanas K; Paschalidis E; Tousoulis D; Kallikazaros I
    Hellenic J Cardiol; 2017; 58(1):4-16. PubMed ID: 28163146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous Implantable Cardioverter Defibrillators for the Prevention of Sudden Cardiac Death: Pediatric Single-Center Experience.
    Wieniawski P; Buczyński M; Grabowski M; Winter J; Werner B
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator.
    Knops RE; Olde Nordkamp LR; de Groot JR; Wilde AA
    Heart Rhythm; 2013 Aug; 10(8):1240-3. PubMed ID: 23707489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of the entirely subcutaneous ICD in borderline indications.
    Willy K; Reinke F; Bögeholz N; Köbe J; Eckardt L; Frommeyer G
    Clin Res Cardiol; 2020 Jun; 109(6):694-699. PubMed ID: 31586219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator.
    Adduci C; Palano F; Silvetti G; Cosentino P; Francia P
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):291-297. PubMed ID: 32519207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey study of the use of a subcutaneous implantable cardioverter-defibrillator in various clinical scenarios by expert electrophysiologists in Poland.
    Kempa M; Opielowska-Nowak B; Budrejko S; Raczak G
    Cardiol J; 2023; 30(2):214-220. PubMed ID: 35975797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Medications and Appropriate Implantable Cardioverter-defibrillator Shocks in Aborted Sudden Cardiac Death Due to Coronary Spasm.
    Sueda S; Kohno H
    Intern Med; 2018 May; 57(10):1361-1369. PubMed ID: 29321418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
    Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
    Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitachyarrhythmic interventions of implantable cardioverter-defibrillator in primary and secondary sudden cardiac death prevention patients].
    Piekarz J; Rydlewska A; Majewski J; Lelakowski J
    Pol Merkur Lekarski; 2012 Jun; 32(192):368-73. PubMed ID: 22891561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.